Table 4 Patient characteristics methylnaltrexone trial
From: Optimal treatment of opioid induced constipation in daily clinical practice – an observational study
Total N = 26 | Oxycodone group N = 16 | Fentanyl group N = 8 | Morphine group N = 2 | ||
|---|---|---|---|---|---|
Age | mean (SD) | 59 (13) | 58 (10) | 58 (18) | 62 (18) |
Sex | Male | 11 | 9 | 2 | 0 |
Female | 15 | 7 | 6 | 2 | |
Treatment setting | Hospital | 20 | 11 | 7 | 2 |
Ambulant | 6 | 5 | 1 | 0 | |
Cancer Type | Gastro-intestinal | 9 | 6 | 3 | 0 |
Breast | 6 | 3 | 2 | 1 | |
Genito-urethral | 6 | 5 | 1 | 0 | |
Other | 5 | 2 | 2 | 1 | |
Concomitant laxatives | PEG | 19 | 12 | 5 | 2 |
Magnesiumoxide | 7 | 4 | 3 | 0 | |
Other | 3 | 3 | 0 | 0 | |
Patients using > 1 laxative | 4 | 3 | 1 | 0 | |
Morphine equivalent daily dose | median (range) | 80 (40–540) | 80 (40–160) | 120 (60–240) | 525 (510–540) |